- ResApp Health (RAP) has entered into a three-year distribution agreement with Sanrai International, assisting RAP’s reach in emerging markets
- Sanrai is a distributor of innovative medical device products with long-standing relationships in more than 50 markets and will assist ResApp in these emerging markets
- ResAppDx utilises machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone’s built-in microphone
- Sanrai will sell, promote and market ResAppDx to its network, except in major markets such as India, Mexico and Brazil
- ResApp shares are trading the grey at 6 cents at 11:00 am AEDT
ResApp Health (RAP) has entered into a three-year distribution agreement with Sanrai International, assisting RAP’s reach in emerging markets.
Sanrai will sell, promote and market ResAppDx to its network, except in major markets such as India, Mexico and Brazil.
New York-based Sanrai is a distributor of medical device products with a number of offices across Latin America, Africa, the Middle East and South Asia, as well as long-standing relationships in more than 50 countries.
ResAppDx utilises machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone’s built-in microphone.
The app is CE marked in Europe and TGA approved for ARTG listing in Australia, with the company using this partnership with Sanrai to obtain regulatory approvals in additional countries, where required. It is anticipated the majority of the use will be in-clinic.
Sanrai CEO Jaspreet Rai said the company is excited about the potential of ResAppDx.
“Our mission is to partner with providers, ministries of health, regulatory bodies, and hospital groups to empower medical suppliers to launch products focusing on what matters most – to better the lives of patients needing innovative solutions to be locally available to survive and thrive,” she said.
ResApp CEO and managing director, Dr Tony Keating said the group is looking forward to partnering with Sanrai which will provide ‘reach and scale in emerging markets’.
“This deal supports one of our core values of health equity – bringing this important technology to those who need it the most,” he said.
“Sanrai’s experience in delivering in emerging markets will be an important part of our future growth plans for the benefit of the 3 billion people who live in these countries.”
ResApp shares are trading the grey at 6 cents at 11:00 am AEDT.